CVS Health Corporation $CVS is Watchtower Advisors LP’s Largest Position

Watchtower Advisors LP boosted its stake in CVS Health Corporation (NYSE:CVS) by 37.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 357,000 shares of the pharmacy operator’s stock after acquiring an additional 97,000 shares during the period. CVS Health accounts for approximately 12.6% of Watchtower Advisors LP’s holdings, making the stock its biggest holding. Watchtower Advisors LP’s holdings in CVS Health were worth $26,914,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Financial Life Planners bought a new position in CVS Health in the third quarter worth about $49,000. Van ECK Associates Corp boosted its position in CVS Health by 19.0% during the 3rd quarter. Van ECK Associates Corp now owns 1,307,896 shares of the pharmacy operator’s stock valued at $98,602,000 after acquiring an additional 209,081 shares in the last quarter. LifePlan Financial LLC grew its holdings in shares of CVS Health by 7.8% during the 3rd quarter. LifePlan Financial LLC now owns 22,486 shares of the pharmacy operator’s stock worth $1,695,000 after acquiring an additional 1,620 shares during the period. Tiemann Investment Advisors LLC purchased a new position in shares of CVS Health during the 3rd quarter worth approximately $215,000. Finally, Capital Research Global Investors raised its position in shares of CVS Health by 24.5% in the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after acquiring an additional 2,253,531 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Price Performance

Shares of CVS opened at $75.74 on Thursday. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The company has a market capitalization of $96.35 billion, a P/E ratio of 54.88, a price-to-earnings-growth ratio of 0.80 and a beta of 0.49. The firm has a 50 day moving average of $78.31 and a 200 day moving average of $77.72. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Morgan Stanley lifted their price target on CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Truist Financial set a $100.00 price objective on CVS Health in a research report on Wednesday, December 10th. The Goldman Sachs Group boosted their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Finally, Mizuho boosted their price objective on shares of CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.91.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.